Lipidcsökkento″k hatása a máj mu″kö désére

Translated title of the contribution: Impact of lipid lowering therapy on liver function

G. Paragh, Péter Fülöp

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Cardiovascular diseases are leading causes of morbidity and mortality in Hungary. Hyperlipoproteinemia plays a key role in the development of these diseases. Based upon the results of previous prospective multicenter trials, effective lipid lowering therapy significantly reduces cardiovascular deaths and total morbidity. This beneficial effect correlates with the degree of the LDL-C reduction, which can be usually reached with high doses of statins. These drugs cause hepatotoxicity in 3% of the patients, when used in high doses. The authors briefly review the effects of the lipid lowering drugs and the potential mechanisms by which these drugs may provoke liver injury. They emphasize the fact, that lipid lowering drugs may be used safely in patients with elevated aminotransferase levels or even in subjects with certain definitive liver diseases. However, the clinicians should be cautious to use the appropriate dose and combination to reduce the possibility of the development of adverse events. With these, we can safely provide the beneficial effects of lipid lowering therapy to those with chronic liver disease and high cardiovascular risk.

Original languageHungarian
Pages (from-to)1205-1212
Number of pages8
JournalOrvosi Hetilap
Volume150
Issue number26
DOIs
Publication statusPublished - Jun 1 2009

Fingerprint

Lipids
Liver
Pharmaceutical Preparations
Liver Diseases
Morbidity
Hyperlipoproteinemias
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hungary
Therapeutics
Transaminases
Multicenter Studies
Chronic Disease
Cardiovascular Diseases
Mortality
Wounds and Injuries
oxidized low density lipoprotein

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lipidcsökkento″k hatása a máj mu″kö désére. / Paragh, G.; Fülöp, Péter.

In: Orvosi Hetilap, Vol. 150, No. 26, 01.06.2009, p. 1205-1212.

Research output: Contribution to journalArticle

Paragh, G. ; Fülöp, Péter. / Lipidcsökkento″k hatása a máj mu″kö désére. In: Orvosi Hetilap. 2009 ; Vol. 150, No. 26. pp. 1205-1212.
@article{8d9f9ac9033b4dd3a9cde5c7f9d4ce79,
title = "Lipidcs{\"o}kkento″k hat{\'a}sa a m{\'a}j mu″k{\"o} d{\'e}s{\'e}re",
abstract = "Cardiovascular diseases are leading causes of morbidity and mortality in Hungary. Hyperlipoproteinemia plays a key role in the development of these diseases. Based upon the results of previous prospective multicenter trials, effective lipid lowering therapy significantly reduces cardiovascular deaths and total morbidity. This beneficial effect correlates with the degree of the LDL-C reduction, which can be usually reached with high doses of statins. These drugs cause hepatotoxicity in 3{\%} of the patients, when used in high doses. The authors briefly review the effects of the lipid lowering drugs and the potential mechanisms by which these drugs may provoke liver injury. They emphasize the fact, that lipid lowering drugs may be used safely in patients with elevated aminotransferase levels or even in subjects with certain definitive liver diseases. However, the clinicians should be cautious to use the appropriate dose and combination to reduce the possibility of the development of adverse events. With these, we can safely provide the beneficial effects of lipid lowering therapy to those with chronic liver disease and high cardiovascular risk.",
keywords = "Cytochrome system, Fatty liver, Hepatotoxicity, Hyperlipoproteinemia, Lipid lowering therapy",
author = "G. Paragh and P{\'e}ter F{\"u}l{\"o}p",
year = "2009",
month = "6",
day = "1",
doi = "10.1556/OH.2009.28629",
language = "Hungarian",
volume = "150",
pages = "1205--1212",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "26",

}

TY - JOUR

T1 - Lipidcsökkento″k hatása a máj mu″kö désére

AU - Paragh, G.

AU - Fülöp, Péter

PY - 2009/6/1

Y1 - 2009/6/1

N2 - Cardiovascular diseases are leading causes of morbidity and mortality in Hungary. Hyperlipoproteinemia plays a key role in the development of these diseases. Based upon the results of previous prospective multicenter trials, effective lipid lowering therapy significantly reduces cardiovascular deaths and total morbidity. This beneficial effect correlates with the degree of the LDL-C reduction, which can be usually reached with high doses of statins. These drugs cause hepatotoxicity in 3% of the patients, when used in high doses. The authors briefly review the effects of the lipid lowering drugs and the potential mechanisms by which these drugs may provoke liver injury. They emphasize the fact, that lipid lowering drugs may be used safely in patients with elevated aminotransferase levels or even in subjects with certain definitive liver diseases. However, the clinicians should be cautious to use the appropriate dose and combination to reduce the possibility of the development of adverse events. With these, we can safely provide the beneficial effects of lipid lowering therapy to those with chronic liver disease and high cardiovascular risk.

AB - Cardiovascular diseases are leading causes of morbidity and mortality in Hungary. Hyperlipoproteinemia plays a key role in the development of these diseases. Based upon the results of previous prospective multicenter trials, effective lipid lowering therapy significantly reduces cardiovascular deaths and total morbidity. This beneficial effect correlates with the degree of the LDL-C reduction, which can be usually reached with high doses of statins. These drugs cause hepatotoxicity in 3% of the patients, when used in high doses. The authors briefly review the effects of the lipid lowering drugs and the potential mechanisms by which these drugs may provoke liver injury. They emphasize the fact, that lipid lowering drugs may be used safely in patients with elevated aminotransferase levels or even in subjects with certain definitive liver diseases. However, the clinicians should be cautious to use the appropriate dose and combination to reduce the possibility of the development of adverse events. With these, we can safely provide the beneficial effects of lipid lowering therapy to those with chronic liver disease and high cardiovascular risk.

KW - Cytochrome system

KW - Fatty liver

KW - Hepatotoxicity

KW - Hyperlipoproteinemia

KW - Lipid lowering therapy

UR - http://www.scopus.com/inward/record.url?scp=68149145374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68149145374&partnerID=8YFLogxK

U2 - 10.1556/OH.2009.28629

DO - 10.1556/OH.2009.28629

M3 - Article

VL - 150

SP - 1205

EP - 1212

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 26

ER -